Neutralizing antibodies for the treatment of COVID-19
… More clinical trial data are needed to determine whether sera from COVID-19-convalescent
patients and neutralizing monoclonal antibodies specific to SARS-CoV-2 antigens can prevent
COVID-19 or reduce the severity of the disease in high-risk populations. … In this Comment, we
summarize the neutralizing antibodies, including monoclonal antibodies (mAbs) and
nanobodies, for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are
currently in preclinical development and in clinical trials, the antibodies’ potential mechanisms of …
patients and neutralizing monoclonal antibodies specific to SARS-CoV-2 antigens can prevent
COVID-19 or reduce the severity of the disease in high-risk populations. … In this Comment, we
summarize the neutralizing antibodies, including monoclonal antibodies (mAbs) and
nanobodies, for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are
currently in preclinical development and in clinical trials, the antibodies’ potential mechanisms of …
More clinical trial data are needed to determine whether sera from COVID-19-convalescent patients and neutralizing monoclonal antibodies specific to SARS-CoV-2 antigens can prevent COVID-19 or reduce the severity of the disease in high-risk populations.
nature.com
以上显示的是最相近的搜索结果。 查看全部搜索结果